Meeting NewsVideo

VIDEO: CDK 4/6 inhibitors help make advanced breast cancer ‘chronic disease’ for many patients

June 16, 2019
CHICAGO — The addition of ribociclib to endocrine therapy significantly improved OS for premenopausal women with hormone receptor-positive…

Meeting News

Abemaciclib stabilizes brain metastases in breast cancer subtype

June 14, 2019
CHICAGO — Abemaciclib resulted in a clinically meaningful effect on intracranial response rate in patients with brain metastases secondary to…

Meeting NewsVideo

VIDEO: MONALEESA-7 shows ‘exciting’ results in premenopausal breast cancer

June 14, 2019
CHICAGO — The MONALEESA-7 trial demonstrated that adding the CDK4/6 inhibitor ribociclib (Kisqali, Novartis) to endocrine therapy improved OS…

Meeting News

One year of adjuvant trastuzumab remains standard of care for HER2-positive breast cancer

June 14, 2019
CHICAGO — One year of trastuzumab continues to be the standard of care for adjuvant treatment among patients with early-stage HER2-positive…

FDA News

FDA approves Kanjinti, biosimilar to Herceptin

June 13, 2019
The FDA approved trastuzumab-anns for the treatment of HER2-overexpressing breast cancer, as well as metastatic gastric or gastroesophageal junction…

Meeting News

Triplet therapy confers benefit among certain patients with advanced breast cancer

June 13, 2019
CHICAGO — The combination of ribociclib, everolimus and exemestane conferred clinical benefit and appeared tolerable among patients with…

Meeting NewsVideo

VIDEO: MacroGenics CEO highlights potential of margetuximab in pretreated HER2-positive breast cancer

June 11, 2019
CHICAGO — Scott Koenig, MD, PhD, president and CEO of MacroGenics, spoke with HemOnc Today at ASCO Annual Meeting about positive results from…

Meeting NewsPerspective

Medicaid expansion reduces racial disparities in access to timely cancer care

June 4, 2019
CHICAGO — States that expanded Medicaid under the Affordable Care Act appeared to eliminate disparities in timely treatment for black patients…

Meeting News

Trastuzumab emtansine provides effective, less toxic neoadjuvant therapy for HER2-positive breast cancer

June 4, 2019
CHICAGO — Trastuzumab emtansine appeared as effective as, but less toxic than, docetaxel, trastuzumab and pertuzumab as neoadjuvant therapy for…

Meeting NewsPerspective

Ribociclib plus endocrine therapy improves survival in advanced breast cancer subtype

June 2, 2019
CHICAGO — Premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer derived a significant survival benefit from…

Meeting News

Same-day breast biopsy program eradicates racial, ethnic disparities

May 31, 2019
CHICAGO — Racial and ethnic disparities in time to breast biopsy disappeared after implementation of a same-day biopsy program, according to a…

In the Journals

Overall cancer rates decreasing, but with ‘striking’ burden among young women

May 30, 2019
For all cancer types, U.S. mortality rates continued to decline among adults and children from 1999 to 2016, with decreasing incidence rates for men…

Feature

Wearable device that harvests cancer cells from blood may improve diagnosis, treatment

May 30, 2019
Researchers have developed a novel wearable device that captures cancer cells from blood, potentially providing better information for treatment…

FDA approves Piqray, first PI3K inhibitor for advanced breast cancer

May 24, 2019
The FDA on Friday approved alpelisib, the first PI3K inhibitor to treat postmenopausal women and men with hormone receptor-positive, HER2-negative…

FDA News

FDA weighs breast implant risks, benefits amid links to cancer, other illnesses

HemOnc Today, May 25, 2019
Earlier this month, the FDA issued a statement maintaining that textured implants do not meet the agency’s banning standard, despite an…

FDA News

Recent FDA approvals in oncology

HemOnc Today, May 25, 2019
The FDA has issued the following approvals for oncology indications: To read more on these FDA actions and others, visit Healio.com/HemOnc and search…

Commentary

Understanding breast implant-associated anaplastic large cell lymphoma

HemOnc Today, May 25, 2019
Sameer A. Patel, MD, FACS
Cosmetic breast augmentation and implant-based breast reconstruction after mastectomy remain two of the most commonly performed surgeries by plastic…

Navigators support, empower minority patients with cancer

HemOnc Today, May 25, 2019
The Metropolitan Chicago Breast Cancer Task Force held an evening art gallery event for its survivors in October. For the task force, it was a…

Cover Story

Efforts to reduce racial disparities in cancer care aim to ‘make the invisible visible’

HemOnc Today, May 25, 2019
The trends are clear — not only do ethnic and racial minority groups face poorer cancer outcomes, they also are less frequently invited to…

In the Journals

High-dose irradiation before HSCT increases risk for subsequent malignancies

May 21, 2019
Survivors of allogeneic hematopoietic cell transplantation who underwent high-dose total body irradiation incurred nearly eight times the risk for…